The stock price divergence of the two listed players in the Indian diagnostics space—Thyrocare Technologies Ltd. and Dr Lal Pathlabs Ltd.—indicates ample inflows in the latter and outflows in the former.
On a year-to-date basis, Dr. Lal Pathlabs has gained over 22 percent while Thyrocare is down 10 percent.
While slowing growth seems to be investors' primary concern with Thyrocare, multiple factors such as business model, management commentary, strategy and return ratios seem to be working well for Dr Lal Pathlabs.
Watch video for more details
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
